ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first ExpreS2-based product. The product, an Ebola virus glycoprotein, is marketed as a part of IBT’s high-quality research protein portfolio and can be used in the development of diagnostic or therapeutic products.

The Ebola virus glycoprotein product can be ordered directly from IBT Bioservices’ website, and there is also a catalogue data sheet available. Follow the links to reach the website or the data sheet, respectively.